Press Releases April 29, 2026 04:15 PM

Omega Flex, Inc. Announces First Quarter 2026 Earnings

Omega Flex Reports Q1 2026 Earnings with Decline in Net Income Amid Rising Costs and Strategic Investments

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
OFLX

Omega Flex, Inc. announced its first quarter 2026 financial results, showing a slight decrease in net sales by 1.0% to $23.09 million and a significant drop in net income by 41.8% to $2.08 million compared to the same period in 2025. The decrease in profitability was primarily due to increased raw material costs, tariffs, marketing expenses, and costs associated with product enhancements and certifications. The company invested strategically in equipment, facilities, and product development to support capacity expansion, improve operational efficiency, and facilitate geographic growth.

Omega Flex, Inc. Announces First Quarter 2026 Earnings
OFLX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 net sales decreased slightly by 1.0% to $23.09 million compared to Q1 2025.
  • Net income decreased significantly by 41.8% to $2.08 million, driven by higher raw material costs, tariffs, and marketing and product-related expenses.
  • The company is making targeted investments to expand capacity, improve operational efficiency, and support geographic growth and product enhancements.
  • Relevant sectors impacted include industrial manufacturing, construction materials, and infrastructure development due to Omega Flex's role in flexible piping solutions.

EXTON, Pa., April 29, 2026 (GLOBE NEWSWIRE) --

  OMEGA FLEX, INC. (OFLX)     Three Months Ended March 31,       2026
 2025
     Net Sales $23,093,000 $23,330,000          Net Income attributable to Omega Flex, Inc. $2,077,000 $3,568,000          Earnings Per Share - Basic and Diluted $0.21 $0.35          Weighted Average Shares - Basic and Diluted  10,094,322  10,094,322     

Dean W. Rivest, CEO, announced that net sales of Omega Flex, Inc. (the “Company”) for the first quarters of 2026 and 2025 were $23,093,000 and $23,330,000, respectively, decreasing $237,000 or 1.0%.  Net income for the first quarters of 2026 and 2025 were $2,007,000 and $3,568,000, respectively, decreasing $1,491,000 or 41.8%. The decrease in net income was mainly due to rising raw material costs, including tariffs, marketing efforts, and product enhancement and certification related expenses.

During the quarter, the Company continued to make targeted investments in equipment and facilities to expand capacity, enhance operational efficiency, and support geographic growth, while pursuing product enhancements intended to strengthen its market position beyond traditional markets.

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s financial condition, results of operations, future performance, growth strategies, business initiatives and anticipated trends. Forward-looking statements can generally be identified by words such as “may,” “should,” “will,” “could,” “estimates,” “predicts,” “potential,” “continue,” “anticipates,” “believes,” “plans,” “expects,” “future,” “intends,” “projects,” the negative of these terms, or other comparable terminology. Forward-looking statements are neither historical facts nor assurances of future performance. Rather, they are based on current beliefs, expectations and assumptions regarding the Company’s business, strategies and anticipated events and trends. These statements are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict, many of which are outside of our control, and actual results could differ materially from those expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation, other than as required by law, to update or revise any forward-looking statements to reflect events or circumstances after the date hereof. Further information regarding risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements is included in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

Contact: Dean W. Rivest
(610) 524-7272


Risks

  • Rising raw material costs and tariffs could continue to pressure profit margins impacting the industrial manufacturing sector.
  • Increased marketing and product certification expenses may weigh on near-term profitability and cash flow.
  • Uncertainties related to growth investments and market acceptance of product enhancements pose execution risks.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026